Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3047

1.

Development and validation of a HPLC-UV method for pazopanib quantification in human plasma and application to cancer patients in routine clinical practice.

Escudero-Ortiz V, Pérez-Ruixo JJ, Valenzuela B.

Ther Drug Monit. 2014 Jul 28. [Epub ahead of print]

PMID:
25072946
[PubMed - as supplied by publisher]
2.

Rebound burst firing in the reticular thalamus is not essential for pharmacological absence seizures in mice.

Lee SE, Lee J, Latchoumane C, Lee B, Oh SJ, Saud ZA, Park C, Sun N, Cheong E, Chen CC, Choi EJ, Lee CJ, Shin HS.

Proc Natl Acad Sci U S A. 2014 Jul 28. pii: 201408609. [Epub ahead of print]

PMID:
25071191
[PubMed - as supplied by publisher]
3.

Cost of Biologics per Treated Patient across Immune-Mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study.

Wu N, Lee YC, Shah N, Harrison DJ.

Clin Ther. 2014 Jul 22. pii: S0149-2918(14)00377-4. doi: 10.1016/j.clinthera.2014.06.014. [Epub ahead of print]

PMID:
25062652
[PubMed - as supplied by publisher]
4.

Immune modulation by butyrophilins.

Arnett HA, Viney JL.

Nat Rev Immunol. 2014 Jul 25;14(8):559-69. doi: 10.1038/nri3715.

PMID:
25060581
[PubMed - in process]
5.

Transfusions and patient burden in chemotherapy-induced anaemia in France.

Corey-Lisle PK, Desrosiers MP, Collins H, De La Orden M, Payne KA, Levaché CB, Dumont P.

Ther Adv Med Oncol. 2014 Jul;6(4):146-53. doi: 10.1177/1758834014534515.

PMID:
25057301
[PubMed]
Free PMC Article
6.

Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study.

Lorusso V, Duran I, Garzon-Rodriguez C, Lüftner D, Bahl A, Ashcroft J, Hechmati G, Wei R, Thomas E, Hoefeler H.

Mol Clin Oncol. 2014 Sep;2(5):701-708. Epub 2014 Jun 27.

PMID:
25054033
[PubMed]
Free PMC Article
7.

Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States.

Hernandez RK, Quach D, Wade SW, Pirolli M, Quigley J, Narod SA, Liede A.

Breast Cancer Res Treat. 2014 Aug;146(3):637-46. doi: 10.1007/s10549-014-3052-1. Epub 2014 Jul 23.

PMID:
25053278
[PubMed - in process]
8.

Quantitative spectral comparison by weighted spectral difference for protein higher order structure confirmation.

Dinh NN, Winn BC, Arthur KK, Gabrielson JP.

Anal Biochem. 2014 Jul 19. pii: S0003-2697(14)00305-4. doi: 10.1016/j.ab.2014.07.011. [Epub ahead of print]

PMID:
25051254
[PubMed - as supplied by publisher]
9.

PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels.

Marais AD, Kim JB, Wasserman SM, Lambert G.

Pharmacol Ther. 2014 Jul 18. pii: S0163-7258(14)00130-2. doi: 10.1016/j.pharmthera.2014.07.004. [Epub ahead of print] Review.

PMID:
25046268
[PubMed - as supplied by publisher]
10.

Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.

Tatarewicz SM, Mytych DT, Manning MS, Swanson SJ, Moxness MS, Chirmule N.

Bioanalysis. 2014 Jun;6(11):1509-23. doi: 10.4155/bio.14.114.

PMID:
25046051
[PubMed - in process]
11.

Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study.

Lüftner D, Lorusso V, Duran I, Hechmati G, Garzon-Rodriguez C, Ashcroft J, Bahl A, Ghelani P, Wei R, Thomas E, Hoefeler H.

Springerplus. 2014 Jun 30;3:328. doi: 10.1186/2193-1801-3-328. eCollection 2014.

PMID:
25045611
[PubMed]
Free PMC Article
12.

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity.

Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, O'Neill JW, Mallari R, Zhao X, Branstetter DG, Rossi JM, Long AM, Huang X, Holland PM.

Cancer Cell. 2014 Jul 15. pii: S1535-6108(14)00191-3. doi: 10.1016/j.ccr.2014.04.028. [Epub ahead of print]

PMID:
25043603
[PubMed - as supplied by publisher]
13.

Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures.

Du Z, Treiber D, McCarter J, Yadlin DF, Saleem RA, McCoy RE, Zhang Y, Tharmalingam T, Leith M, Follstad BD, Dell B, Grisim B, Zupke C, Heath C, Morris AE, Reddy P.

Biotechnol Bioeng. 2014 Jul 9. doi: 10.1002/bit.25332. [Epub ahead of print]

PMID:
25042542
[PubMed - as supplied by publisher]
14.

Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.

Wang Y, Zhu J, Liu JJ, Chen X, Mihalic J, Deignan J, Yu M, Sun D, Kayser F, McGee LR, Lo MC, Chen A, Zhou J, Ye Q, Huang X, Long AM, Yakowec P, Oliner JD, Olson SH, Medina JC.

Bioorg Med Chem Lett. 2014 Jul 1. pii: S0960-894X(14)00703-3. doi: 10.1016/j.bmcl.2014.06.073. [Epub ahead of print]

PMID:
25042256
[PubMed - as supplied by publisher]
15.

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A.

Eur J Cancer. 2014 Jul 15. pii: S0959-8049(14)00754-0. doi: 10.1016/j.ejca.2014.06.010. [Epub ahead of print]

PMID:
25037684
[PubMed - as supplied by publisher]
16.

Non-parametric Tests for Evaluation of Biosimilarity in Variability of Follow-on Biologics.

Zhang N, Yang J, Chow SC, Chi E.

J Biopharm Stat. 2014 Jul 18. [Epub ahead of print]

PMID:
25036940
[PubMed - as supplied by publisher]
17.

Classification of glass particles in parenteral product vials by visual, microscopic, and spectroscopic methods.

Li GG, Cao S, Jiao N, Wen ZQ.

PDA J Pharm Sci Technol. 2014 Jul-Aug;68(4):362-72. doi: 10.5731/pdajpst.2014.00986.

PMID:
25035258
[PubMed - in process]
18.

Association of Anticyclic Citrullinated Peptide Antibodies and/or Rheumatoid Factor Status and Clinical Presentation in Early Arthritis: Results from the ESPOIR Cohort.

Mouterde G, Lukas C, Goupille P, Flipo RM, Rincheval N, Daurès JP, Combe B.

J Rheumatol. 2014 Jul 15. pii: jrheum.130884. [Epub ahead of print]

PMID:
25028372
[PubMed - as supplied by publisher]
19.

USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor.

Jaworski J, de la Vega M, Fletcher SJ, McFarlane C, Greene MK, Smyth AW, Van Schaeybroeck S, Johnston JA, Scott CJ, Rappoport JZ, Burrows JF.

Oncotarget. 2014 Jul 3. [Epub ahead of print]

PMID:
25026282
[PubMed - as supplied by publisher]
Free Article
20.

High-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations.

Alekseychyk L, Su C, Becker GW, Treuheit MJ, Razinkov VI.

J Biomol Screen. 2014 Jul 14. pii: 1087057114542431. [Epub ahead of print]

PMID:
25023322
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk